Top Markets
#1 Black Phoenix Black Phoenix +166.82%
#2 Islamic Coin Islamic Coin +158.09%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +29.06%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.86%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.69%
#8 Test Test +13.79%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +10.94%
#10 Bluwhale Bluwhale +10.65%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
Rank in Stocks #41696
InNexus Biotechnology, Inc. is a development-stage company dedicated to... InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Share Price
$0.0001
Last synced: 2025-11-07
Market Cap
$12.63K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade InNexus Biotechnology, Inc. (IXSBF)

Category

Healthcare
Revenue for InNexus Biotechnology, Inc. (IXSBF)
Revenue in Aug 2026 TTM: 0
According to InNexus Biotechnology, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for InNexus Biotechnology, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US